Organogenesis tests Vitrix in deep foot ulcers:
This article was originally published in Clinica
Organogenesis has begun a US trial of its Vitrix skin replacement product in diabetic patients who have deep, non-healing wounds in their feet. Deep diabetic foot ulcers can extend through the layers of the skin to underlying bone, tendon or muscle. Vitrix, a single-layer product, can be folded upon itself and inserted into deep wounds. The Canton, Massachusetts firm already markets a skin substitute, Apligraf, for the treatment of diabetic foot and venous ulcers that do not extend below the layers of skin.
You may also be interested in...
A medtech industry group is asking the Trump administration to clarify if small medical device companies that have equity investors qualify for small business loans and forgiveness under the coronavirus relief package.
Amarin had argued that Vascepa’s sales success showed that its patents were not obvious, but the court found otherwise, even as it concluded that Hikma, Dr. Reddy's and West-Ward has infringed on the fish oil pill's patents.
Grail announced results from an initial validation study that showed its early-detection blood test could identify 12 of the deadliest cancers with a low rate of false-positive results.